Platelet-activating factor antagonists: Current status in asthma

BioDrugs

Volumn 14, Issue 1, 2000, Pages 21-30

  Gómez, Federico P ^a   Rodriguez Roisin, Robert ^b,c  

^a FAVALORO UNIVERSITY   (Argentina)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APAFANT; CORTICOSTEROID; FOROPAFANT; GINKGOLIDE; GINKGOLIDE B; ISRAPAFANT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MODIPAFANT; POBILUKAST; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TULOPAFANT; ZAFIRLUKAST; ZILEUTON;

ANIMAL MODEL; ASTHMA; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HUMAN; MICROVASCULATURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT INDICATION;

EID: 0033898432     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014010-00003     Document Type: Review

References (69)

1. Platelet-activating factor in inflammation and pulmonary disorders
2. Platelet-activating factor as a mediator of allergic disease
3. Increased levels of blood platelet activating factor in bronchial asthmatic with active symptoms
4. Platelet-activating factor in bronchoalveolar lavage fluid from asthmatic subjects
5. Platelet-activating factor causes ventilation-perfusion mismatch in humans
6. Contributions of multiple inert gas elimination technique to pulmonary medicine. 3: Bronchial asthma
7. Acute severe asthma: Pathophysiology and pathobiology of gas exchange abnormalities
8. Production of platelet-activating factor by chick retina
9. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor and interleukin 1α
10. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children
11. Specific binding of phospholipid platelet-activating factor by human platelets
12. Binding and metabolism of platelet-activating factor by human neutrophils
13. Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086. Correlation between receptor binding and function
14. Isolation and properties of platelet-activating factor receptor cDNAs
15. Platelet-activating factor receptor: Gene expression and signal transduction
16. Platelet-activating factor induces an increase in intracellular calcium and expression of regulatory genes in human B lymphoblastoid cells
17. Platelet-activating factor induces phospholipid turnover, calcium flux, arachidonic acid liberation, eicosanoid generation, and oncogene expression in a human B cell line
18. Platelet-activating factor may participate in signal transduction processes in rabbit leukocytes
19. Evidence for two platelet activating factor receptors on eosinophils: Dissociation between PAF-induced intracellular calcium mobilization degranulation and superoxides anion generation in eosinophils
20. Specific receptors of platelet activating factor, receptor heterogenicity and signal transduction mechanisms
21. 3H] dihydrokadsurenone to rabbit platelet membranes and its inhibition by the receptor agonists and antagonists of platelet-activating factor
22. 3H] WEB 2086
23. 3H-PAF binding
24. MK 287: A potent, specific, and orally active receptor antagonist of platelet-activating factor
25. Platelet-activating factor antagonists
26. Effect of a ginkolide mixture (BN 52063) in antagonizing skin and platelet response to platelet activating factor in man
27. Effects of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects
28. Effect of BN 52063, A specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients: A preliminary study
29. Effects of a PAF-antagonist (BN-52063) on bronchoconstriction and platelet activation during exercise induced asthma
30. Effects of PAF antagonist, BN52021, on the PAF-, methacholine- and allergen-induced bronchoconstriction in asthmatic children
31. Inhibitory effects of the new PAF acether antagonist WEB-2086 on pharmacologic changes induced by PAF inhalation in human beings
32. Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses
33. The effect of the orally active platelet activating factor antagonist WEB 2086 in the treatment of asthma
34. Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma: A multicenter, double-blind placebo-controlled study in Japan
35. Inhibitory effect of UK,74505, a potent and specific oral platelet-activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans
36. Effect of a platelet-activating factor (PAF) antagonist UK-74505, on allergen-induced early and late response
37. The effect of RP 59227, a platelet-activating factor antagonist, against antigen challenge and eosinophil and neutrophil chemotaxis in asthmatics
38. Effect of a novel potent platelet-activating factor antagonist, Modipafant, in clinical asthma
39. Effect of a ptatelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma
40. Effects of a potent platelet-activating factor antagonist, SR 27417A, on allergen-induced asthmatic responses
41. Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: A pilot study
42. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma
43. Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans
44. Inhaled platelet-activating factor worsens gas exchange in mild asthma
45. Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilatation
46. Platelet-activating factor in late asthmatic response
47. Inflammation and asthma
48. Leukotriene and other products of 5-lipoxygenase pathway
49. Sulphidopeptide leukotrienes in asthma
50. Regional and time-dependent effects of inflammatory mediators on airway microvascular permeability in the guinea pig
51. 4
52. 4 in normal and asthmatic subjects
53. Nonimmunological production of leukotrienes induced by platelet-activating factor
54. 4 formation and luminol dependent chemiluminiscence by human eosinophils
55. 2 production in humans
56. Participation of the cysteinyl leukotrienes in the acute bronchoconstriction response to inhaled platelet activating factor in man
57. 4 receptor antagonist ICI 204,219
58. The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating factor-induced pulmonary abnormalities in mild asthma
59. The role of leukotriene modifiers in the treatment of asthma
60. Salbutamol inhibits pulmonary effects of platelet-activating factor in man
61. Molecular mechanisms of steroid action in asthma
62. Antiinflammatory effects of oxatomide
63. Platelet activating factor revisited
64. Loop diuretics and asthma
65. Effects of inhaled furosemide on platelet-activating factor challenge in mild asthma
66. 4 release in stimulated asthmatic neutrophils by platelet activating factor
67. Platelet-activating factor acetylhydrolase deficiency: A missense mutation near the active site of an anti-inflammatory phospholipase
68. Anti-inflammatory properties of platelet-activating factor acetylhydrolase